ATE547403T1 - Fluoreszente regulatoren der rassf1a-expression und der proliferation humaner krebszellen - Google Patents

Fluoreszente regulatoren der rassf1a-expression und der proliferation humaner krebszellen

Info

Publication number
ATE547403T1
ATE547403T1 AT09789145T AT09789145T ATE547403T1 AT E547403 T1 ATE547403 T1 AT E547403T1 AT 09789145 T AT09789145 T AT 09789145T AT 09789145 T AT09789145 T AT 09789145T AT E547403 T1 ATE547403 T1 AT E547403T1
Authority
AT
Austria
Prior art keywords
group
heterogroup
rassf1a
expression
aryl group
Prior art date
Application number
AT09789145T
Other languages
German (de)
English (en)
Inventor
Milton Brown
Kathryn Sheikh
Mikell Paige
Partha Banerjee
Shankar Jagadeesh
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Application granted granted Critical
Publication of ATE547403T1 publication Critical patent/ATE547403T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Electroluminescent Light Sources (AREA)
AT09789145T 2008-08-15 2009-08-14 Fluoreszente regulatoren der rassf1a-expression und der proliferation humaner krebszellen ATE547403T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18905908P 2008-08-15 2008-08-15
PCT/US2009/004681 WO2010019271A1 (en) 2008-08-15 2009-08-14 Fluorescent regulators of rassf1a expression and human cancer cell proliferation

Publications (1)

Publication Number Publication Date
ATE547403T1 true ATE547403T1 (de) 2012-03-15

Family

ID=41279343

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09789145T ATE547403T1 (de) 2008-08-15 2009-08-14 Fluoreszente regulatoren der rassf1a-expression und der proliferation humaner krebszellen

Country Status (9)

Country Link
US (1) US10457639B2 (enExample)
EP (2) EP2484666A1 (enExample)
JP (2) JP2012500197A (enExample)
CN (1) CN102186820B (enExample)
AT (1) ATE547403T1 (enExample)
AU (1) AU2009282451B2 (enExample)
BR (1) BRPI0917411A2 (enExample)
CA (1) CA2734225A1 (enExample)
WO (1) WO2010019271A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
PE20130649A1 (es) 2010-03-08 2013-07-13 Monsanto Technology Llc Moleculas polinucleotidicas para regulacion genetica en plantas
US8637679B2 (en) 2011-03-11 2014-01-28 Council Of Scientific And Industrial Research Process for the isolation of organic compounds useful for the treatment of cancer
EP3434779A1 (en) 2011-09-13 2019-01-30 Monsanto Technology LLC Methods and compositions for weed control
WO2013040116A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
EP2755466A4 (en) 2011-09-13 2015-04-15 Monsanto Technology Llc METHOD AND COMPOSITIONS FOR WEED CONTROL
CN103957697B (zh) 2011-09-13 2017-10-24 孟山都技术公司 用于杂草控制的方法和组合物
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
MX343072B (es) 2011-09-13 2016-10-21 Monsanto Technology Llc Metodos y composiciones para controlar malezas.
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US10240162B2 (en) 2012-05-24 2019-03-26 A.B. Seeds Ltd. Compositions and methods for silencing gene expression
UA118841C2 (uk) 2013-01-01 2019-03-25 Ей.Бі. СІДС ЛТД. Спосіб формування рослини, яка має підвищену стійкість до комахи-шкідника
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
EP2967082A4 (en) 2013-03-13 2016-11-02 Monsanto Technology Llc METHOD AND COMPOSITIONS FOR WEED CONTROL
WO2014164761A1 (en) 2013-03-13 2014-10-09 Monsanto Technology Llc Methods and compositions for weed control
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
WO2014151317A1 (en) * 2013-03-15 2014-09-25 Rush University Medical Center Methods for treating cancer
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
JP6668236B2 (ja) 2013-07-19 2020-03-18 モンサント テクノロジー エルエルシー Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法
MX390055B (es) 2013-11-04 2025-03-20 Monsanto Technology Llc Composiciones y metodos para controlar infestaciones de plagas y parasitos de los artropodos.
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
CN105979770B (zh) 2014-01-15 2019-07-05 孟山都技术公司 用于使用epsps多核苷酸的杂草控制的方法和组合物
BR112016022711A2 (pt) 2014-04-01 2017-10-31 Monsanto Technology Llc composições e métodos para controle de pragas de inseto
WO2015200223A1 (en) 2014-06-23 2015-12-30 Monsanto Technology Llc Compositions and methods for regulating gene expression via rna interference
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
AU2015296700B2 (en) 2014-07-29 2021-10-21 Monsanto Technology Llc Compositions and methods for controlling insect pests
US10968449B2 (en) 2015-01-22 2021-04-06 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US10883103B2 (en) 2015-06-02 2021-01-05 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
EP3302030A4 (en) 2015-06-03 2019-04-24 Monsanto Technology LLC METHOD AND COMPOSITIONS FOR INTRODUCING NUCLEIC ACIDS IN PLANTS
US10173978B2 (en) * 2015-08-05 2019-01-08 Georgetown University Small molecule androgen receptor inhibitors and methods of use thereof
US11464750B2 (en) 2017-06-12 2022-10-11 Shohei Miyata Anticancer agent and use thereof
CN107266356B (zh) * 2017-07-25 2020-06-26 山西省生物研究院有限公司 一种作为自分泌运动因子抑制剂的咔唑类化合物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2235815A1 (de) * 1972-07-21 1974-01-31 Bayer Ag Polyazofarbstoffe
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
GB9215361D0 (en) 1992-07-20 1992-09-02 Wellcome Found Heterocyclic compounds
WO1995003279A1 (en) 1993-07-26 1995-02-02 Eisai Co., Ltd. Sulfonamide and sulfonic ester derivatives each having tricyclic hetero ring
JP3690825B2 (ja) * 1993-07-26 2005-08-31 エーザイ株式会社 三環式ヘテロ環含有スルホンアミドおよびスルホン酸エステル誘導体
CA2186412A1 (en) 1995-10-31 1997-05-01 Katherine S. Takaki Ethylamino carbazole melatonergic agents
WO1999032463A1 (en) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
WO2000063171A1 (en) * 1999-04-20 2000-10-26 Meiji Seika Kaisha, Ltd. Tricyclic compounds
CA2394778A1 (en) 1999-12-16 2002-06-14 Shiro Miyoshi Novel substituted tricyclic compounds
WO2001083452A1 (en) 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds
US6506901B2 (en) * 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
EP1847263A3 (en) 2000-12-18 2009-08-26 Institute of Medicinal Molecular Design, Inc. Inhibitors against the production and release of inflammatory cytokines
AU2002228316A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
JPWO2002074306A1 (ja) 2001-03-19 2004-07-08 旭化成ファーマ株式会社 脂肪肝治療薬
GB0319151D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US20100063126A1 (en) 2004-06-29 2010-03-11 Jadolabs Gmbh Carbazole-Derived Pharmaceutical Compositions
ATE381540T1 (de) 2004-08-18 2008-01-15 Ciba Sc Holding Ag Oximesther-fotoinitiatoren
ITMI20051523A1 (it) 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
GB2443588B (en) 2005-09-01 2010-04-21 Council Scient Ind Res A pharmaceutical composition useful for the treatment of prostate cancer
CN1807413B (zh) * 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
CA2625219A1 (en) * 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pstat3/il-6 inhibitors
WO2008051523A2 (en) 2006-10-23 2008-05-02 Georgetown University Carbazole derivatives useful as medicaments in cancer therapy
IL186935A0 (en) * 2006-10-31 2008-02-09 Veridex Llc Prostate cancer field effect analysis methods and kits
CA2710520A1 (en) * 2007-12-28 2009-07-09 John Wayne Cancer Institute Use of methylation status of mint loci and tumor-related genes as a marker for melanoma and breast cancer
AU2009228765B2 (en) 2008-03-24 2012-05-31 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
CN102186820B (zh) 2013-08-28
HK1158206A1 (en) 2012-07-13
CA2734225A1 (en) 2010-02-18
BRPI0917411A2 (pt) 2015-12-01
WO2010019271A8 (en) 2011-03-31
AU2009282451B2 (en) 2014-02-13
EP2323982B1 (en) 2012-02-29
EP2484666A1 (en) 2012-08-08
JP2014148545A (ja) 2014-08-21
JP2012500197A (ja) 2012-01-05
US10457639B2 (en) 2019-10-29
US20110152339A1 (en) 2011-06-23
AU2009282451A1 (en) 2010-02-18
WO2010019271A1 (en) 2010-02-18
CN102186820A (zh) 2011-09-14
EP2323982A1 (en) 2011-05-25

Similar Documents

Publication Publication Date Title
BRPI0917411A2 (pt) composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit.
MX2009013341A (es) Derivados de 6-(pirrolopiridinil)-pirimidinil-2-amina.
CU24269B1 (es) 3- pirimidin- 4-il- oxazolidin- 2- onas inhibidores de la idh mutante
EA201390550A1 (ru) Способы ингибирования пролиферации клеток в egfr-стимулируемых злокачественных опухолях
MY176944A (en) Substituted pyrimidines for the treatment of diseases such as cancer
MX2010003368A (es) Derivados de imidazol.
ZA200701137B (en) Triazolophthalazines
ECSP109953A (es) Derivados de piridazinona
WO2010000364A8 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
TR201011157T1 (tr) Diglisidik eter türevi terapotikleri ve bunların kullanılma yöntemleri.
UA113156C2 (xx) Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
GT200800105A (es) Triazolopiridazinas como moduladores de tirosina cinasa
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
MX2009010034A (es) Pirimidodiazepinas sustituidas utiles inhibidores de la plk1.
EA201590262A1 (ru) Комбинированное лечение меланомы, включающее введение кобиметиниба и вемурафениба
EA201390031A1 (ru) МОДИФИКАТОРЫ АРИЛУГЛЕВОДОРОДНОГО РЕЦЕПТОРА (AhR) В КАЧЕСТВЕ НОВЫХ ПРОТИВОРАКОВЫХ ТЕРАПЕВТИЧЕСКИХ СРЕДСТВ
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
EA200801968A1 (ru) Пирролопиримидиновые производные, используемые в качестве ингибиторов hsp90
EA201101585A1 (ru) 3-(1,2,3-триазол-4-ил)пирроло[2,3-b]пиридинпроизводные
ATE443717T1 (de) Metastin derivate und ihre verwendung
PT2231662E (pt) 8-anilinoimidazopiridinas e o seu uso como agentes anticancerígenos e/ou anti-inflamatórios
MX2010007927A (es) Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina.
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
EA201170344A1 (ru) Азаиндольные ингибиторы iap
TW200730532A (en) Camptothecin derivatives as chemoradiosensitizing agents